Scholar Rock price target lowered to $49 from $53 at BofA

BofA analyst Tazeen Ahmad lowered the firm’s price target on Scholar Rock (SRRK) to $49 from $53 and keeps a Buy rating on the shares. After speaking with a former director at FDA’s Office of Inspections and Investigations and with a former site inspector who previously inspected Catalent Indiana to better understand timelines and next steps for Scholar Rock following CI’s OAI classification, the firm now assumes “a bit more conservative” mid-2027 apitegromab launch timeline, the analyst tells investors.